Faculty discussed the clinical challenges associated with the use of methotrexate and 5-FU, emphasizing the need for education, preparation, continual monitoring, and synchronization through a collaborative exchange to improve outcomes and safety for patients on these two agents.
Wendy H. Vogel, MSN, FNP, AOCNP®, Oncology Nurse Practitioner, Wellmont Cancer Institute, Kingsport, Tennessee
Based on a roundtable discussion conducted at the first annual JADPRO Live 2014 educational symposium in St. Petersburg, Florida, this supplement centers on strategies for preventing and treating severe side effects associated with methotrexate and fluorouracil (5-FU) from the unique perspectives and shared goals of key members of the health-care team: a clinical pharmacist, a medical oncologist, and a nurse practitioner. Representing these team members on the roundtable panel were:
Christopher J. Campen, PharmD, BCPS, BCOP: Dr. Campen is a Clinical Oncology Pharmacist and Information Technology (IT) Analyst at the University of Arizona Cancer Center, Tucson. Chris is currently on the editorial board of JADPRO;
Lee S. Schwartzberg, MD, FACP: Dr. Schwartzberg is Professor of Medicine at the University of Tennessee Health Science Center and Medical Director of The West Clinic in Memphis, Tennessee. Lee has been in private practice in hematology and medical oncology since 1987 and has served as the Medical Director of The West Clinic since 2000; and
Wendy H. Vogel, MSN, FNP, AOCNP® (moderator): Oncology Nurse Practitioner, Wellmont Cancer Institute, Kingsport, Tennessee. Wendy is also on the editorial board of JADPRO and serves as co-chair for JADPRO Live.